Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Axonics Modulation Technologies Inc (AXNX) Insider Trading Activity

    Healthcare • Medical Devices • 797 employees

    Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

    Total Value

    -$46,611,855.00

    Total Shares

    -656,505

    Average Trade Value

    -$3,585,527.31

    Most Active Insider

    Cohen Raymond W

    Total Activity: $20,783,901

    Largest Single Transaction

    $20,783,901

    by Cohen Raymond W on Nov 15, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Nov 15, 2024 17,861 $1,268,131 0 Sale to Issuer
    Chief Medical Officer
    Nov 15, 2024 34,428 $2,444,388 0 Sale to Issuer
    Nov 15, 2024 14,861 $1,055,131 0 Sale to Issuer
    Evp, Chief Mktg/strtgy Officer
    Nov 15, 2024 77,403 $5,495,613 0 Sale to Issuer
    Chief Operating Officer
    Nov 15, 2024 83,854 $5,953,634 0 Sale to Issuer
    Chief Operating Officer
    Nov 15, 2024 608 $43,168 0 Sale to Issuer
    Chief Financial Officer
    Nov 15, 2024 40,362 $2,865,702 0 Sale to Issuer
    Nov 15, 2024 14,944 $1,061,024 0 Sale to Issuer
    Chief Executive Officer
    Nov 15, 2024 292,731 $20,783,901 0 Sale to Issuer
    Nov 15, 2024 19,861 $1,410,131 0 Sale to Issuer
    Nov 15, 2024 6,600 $468,600 0 Sale to Issuer
    Chief Commercial Officer
    Nov 15, 2024 43,450 $3,084,950 0 Sale to Issuer
    Nov 15, 2024 9,542 $677,482 0 Sale to Issuer